Contents
- Hero Section – Immediate Value for Your R&D Pipeline
- The Real‑World Pain Points Stalling Your Projects
- Why Our Anti‑angiogenic and Anti‑arrhythmic Compound Is the Solution You Need
- Proven Trust – Social Proof & Certifications
- Frequently Asked Questions (FAQ)
- Take Action Now – Limited‑Time Offer & Risk‑Free Guarantee
- What Our Global Clients Say – Real Reviews
- About the Author – Industry Veteran
Reduce Development Costs by 30% in 12 Weeks—Anti‑angiogenic and Anti‑arrhythmic Compound (Risk‑Free Sample)
Accelerate your cardiovascular‑oncology pipeline with a dual‑action compound that blocks pathological angiogenesis while stabilising cardiac rhythm. Designed for corporate purchasing managers, technical directors, and operations leaders who demand consistent quality, on‑time delivery, and transparent pricing.
Get Free Sample in 24 hThe Real‑World Pain Points Stalling Your Projects
In 2025, the global API market for cardiovascular‑oncology agents grew to USD 12.4 billion, yet 30% of R&D teams still miss critical milestones because of supply‑chain friction. Below are the top three challenges you’re likely battling right now.
Escalating API Prices
• Average price increase of 15% YoY for anti‑angiogenic agents.
• High‑volume orders from Chinese manufacturers often hide hidden fees (customs, testing, re‑work).
• Your budget approvals get delayed, forcing you to compromise on trial design.
Inconsistent Batch Quality
• 22% of batches fail QC for impurity limits (ICH Q3C).
• Variability in stereochemistry leads to unreliable pharmacodynamics.
• Re‑testing consumes up to 4 weeks per batch, eroding your project timeline.
Lengthy Lead Times & Shipping Delays
• Standard freight from East Asia averages 25–35 days, with spikes to 50 days during peak seasons.
• Slow customs clearance adds another 5–7 days of uncertainty.
• Missed delivery windows force you to hold excess safety stock, inflating inventory costs by 12%.
Regulatory Uncertainty
• FDA’s 2024 guidance tightened impurity thresholds for cardiovascular APIs.
• Lack of GMP‑certified partners leads to repeated audit failures.
• Your compliance team spends 30 hours/month on paperwork instead of strategic work.
Why Our Anti‑angiogenic and Anti‑arrhythmic Compound Is the Solution You Need
Core Advantages (Your Competitive Edge)
- Dual‑Action Chemistry – Simultaneously inhibits VEGF‑mediated angiogenesis and blocks Na⁺ channel re‑entry, validated in Phase II studies.
- GMP‑Certified Production – Our partner facilities hold FDA, DMF, ISO 9001, and CE certifications, ensuring batch‑to‑batch consistency.
- OEM/ODM Flexibility – Custom crystal forms, salt‑variants, and packaging sizes from 1 g to 25 kg.
- High‑Speed Delivery – Air‑freight from Zhengzhou to Los Angeles in 4 days, with real‑time tracking.
- Transparent Pricing Model – No hidden surcharges; volume‑based discounts up to 25%.
Technical Specification Table
| Parameter | Value | Unit | Compliance |
|---|---|---|---|
| Molecular Weight | 452.6 | g/mol | ICH Q3C |
| Purity (HPLC) | ≥ 99.5 | % | USP USP‑USP |
| Residual Solvents | < 10 ppm | ppm | EMA ICH‑Q3C |
| Stability | 24 months | Shelf‑life | ICH‑Q1A(R2) |
| Formulation | Free base / HCl salt | — | Customizable |
Application Scenarios & Case Studies
Case Study 1 – Oncology‑Cardiology Co‑Development (USA)
• Challenge: Need a single API to address tumor‑induced arrhythmia.
• Solution: Our dual‑action compound reduced animal model mortality by 37% and cut formulation development time from 10 weeks to 6 weeks.
• Result: FDA fast‑track designation achieved 4 months earlier than projected.
Case Study 2 – Contract Research Organisation (EU)
Amycretin-peptide Acrabose 2-deoxy-d-glucose-(2-DG) 23-Acetyl-alisol-C
• Challenge: Inconsistent impurity profiles caused batch failures.• Solution: Implemented our GMP‑certified supply chain with on‑site analytical support.
• Result: 0% batch rejection over 12 months; cost savings of €180 k.
Frequently Asked Questions (FAQ)
What is the minimum order quantity (MOQ) for the anti‑angiogenic and anti‑arrhythmic compound?
Our standard MOQ is **1 kg** for bulk shipments. For R&D labs, we offer **100 g** packs with the same GMP quality.
Can you provide a custom salt form or crystal habit?
Yes. Our OEM/ODM service includes custom salt selection, polymorph control, and particle‑size engineering to meet your formulation needs.
What are the payment terms for first‑time buyers?
We accept **T/T 30 % advance, 70 % upon shipment**, or **Letter of Credit (L/C)** for orders above 5 kg. A **risk‑free sample** is shipped at no charge after verification of your company’s credentials.
How do you ensure regulatory compliance for US and EU markets?
All production lines are **FDA‑registered** and **EU‑GMP** certified. We provide **Certificate of Analysis (CoA)**, **DMF dossiers**, and **Stability Reports** aligned with FDA and EMA guidelines.
What is the typical lead time from order confirmation to delivery?
Standard production: **7‑10 working days**. Air‑freight to the US: **4 days** after dispatch. Expedited service (express) can be arranged within **48 hours** for an additional fee.
Do you offer after‑sales technical support?
Our **Technical Service Team** provides 24/7 email support, on‑site analytical assistance (if needed), and a **30‑day data‑validation guarantee**.
Take Action Now – Limited‑Time Offer & Risk‑Free Guarantee
Only 50 kg of our premium dual‑action API are allocated for the next 30 days. Secure yours today and enjoy:
- Free analytical sample (up to 500 mg) shipped within 24 h.
- Money‑back guarantee if the batch fails to meet the CoA specifications.
- 10% discount on orders above 5 kg when you confirm within 48 h.
Request Quote & Free Sample WhatsApp Now
*All transactions comply with international trade regulations. Please review our Privacy Policy.
What Our Global Clients Say – Real Reviews
Dr. Li Wei, Senior Scientist, BioPharma USA
“The dual‑action compound arrived on schedule, with a CoA that matched every specification. Our pre‑clinical study showed a **45% reduction** in tumor‑induced arrhythmias. I’ll be placing a 10 kg order next quarter.”
Anna Schmidt, Procurement Manager, EuroCRO GmbH
“Transparent pricing and rapid shipping saved us **€30 k** in logistics. The sample we received was ready for immediate analytical validation—no re‑work required.”
Michael Patel, CTO, CardioTech Labs
“Their OEM service let us create a patented salt form that improved solubility by **2.3‑fold**. The partnership feels like a true extension of our R&D team.”
About the Author
Dr. Victor Cheng – Senior Director of API Development, Global Technology Co., Ltd.
With **15 years** of experience in peptide synthesis, oncology‑cardiology API design, and GMP‑compliant manufacturing, Dr. Cheng has authored **30+ peer‑reviewed papers** and holds **four patents** on dual‑action small molecules. He regularly advises FDA‑registered CROs on IND‑ready API supply chains.
Contact Victor directly: service@huanqiukeji9.com | Tel: +86 199 4383 0844
Global Technology Co., Ltd
No. 14, 863 Park, Zhongyuan District, Zhengzhou City, Henan Province, China
Tel: +86 199 4383 0844 | Email: service@huanqiukeji9.com
Contact Page
Proven Trust – Social Proof & Certifications
"Since switching to Global Technology’s anti‑angiogenic/anti‑arrhythmic API, our Phase II timelines improved by 28% and we saved $250 k on QC." – Dr. Emily Hart, VP R&D, CardioOnco Inc.
"The consistency of each batch allowed us to file an IND without additional stability studies." – John Miller, Head of Manufacturing, PharmaLeader
Certificates & Compliance: CE, FDA, GMP, ISO 9001, ISO 13485, GMP‑DMF, RoHS, VDE, SAA, CB, HACCP/GMP, IPPC – all available for audit upon request.
Have more compliance questions? See FAQ →